TARO-TESTOSTERONE CYPIONATE INJECTION SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

TESTOSTERONE CYPIONATE

から入手可能:

TARO PHARMACEUTICALS INC

ATCコード:

G03BA03

INN（国際名）:

TESTOSTERONE

投薬量:

100MG

医薬品形態:

SOLUTION

構図:

TESTOSTERONE CYPIONATE 100MG

投与経路:

INTRAMUSCULAR

パッケージ内のユニット:

15G/50G

処方タイプ:

Schedule G (CDSA IV)

治療領域:

ANDROGENS

製品概要:

Active ingredient group (AIG) number: 0106401001; AHFS:

認証ステータス:

APPROVED

承認日:

2020-01-29

製品の特徴

PRODUCT MONOGRAPH TARO-TESTOSTERONE CYPIONATE INJECTION
Testosterone Cypionate Injection
100 mg / mL sterile solution
Taro Standard
Androgens
Taro Pharmaceutical Inc.
130 East Drive
Brampton, ON
L6T 1C1 Canada
Date of Revision:
May 26, 2022
Submission Control No: 263625
_Page 1 of 20_
_Page 2 of 20_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................3
INDICATIONS AND CLINICAL
USE..........................................................................3
CONTRAINDICATIONS..............................................................................................4
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................4
WARNINGS AND PRECAUTIONS
.............................................................................4
ADVERSE REACTIONS
..............................................................................................8
DRUG INTERACTIONS
..............................................................................................9
DOSAGE AND ADMINISTRATION
.........................................................................
10
OVERDOSAGE
.........................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
........................................................ 12
STORAGE AND STABILITY
....................................................................................
13
SPECIAL HANDLING INSTRUCTIONS
................................................................... 14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................... 14
PART II: SCIENTIFIC INFORMATION
.........................................................................
15
PHARMACEUTICAL INFORMATION
.....................................................................
15
CLINICAL TRIALS
.............................................................